Davenport & CO LLC Neu Base Therapeutics, Inc. Transaction History

Davenport & CO LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 27, 2023	SELL	$0.17 - $0.39 $1,785 - $4,095	-10,500 Reduced 25.93%	30,000 $5,000
Q3 2022 Oct 11, 2022	SELL	$0.41 - $1.3 $2,050 - $6,500	-5,000 Reduced 10.99%	40,500 $16,000
Q1 2022 May 02, 2022	SELL	$1.26 - $2.95 $3,780 - $8,850	-3,000 Reduced 6.19%	45,500 $86,000
Q4 2021 Feb 10, 2022	SELL	$2.6 - $4.18 $26,000 - $41,800	-10,000 Reduced 17.09%	48,500 $136,000
Q3 2021 Oct 14, 2021	BUY	$3.27 - $4.76 $4,905 - $7,140	1,500 Added 2.63%	58,500 $211,000
Q2 2021 Jul 28, 2021	SELL	$4.63 - $7.34 $11,575 - $18,350	-2,500 Reduced 4.2%	57,000 $273,000
Q4 2020 Jan 13, 2021	BUY	$6.92 - $9.25 $411,740 - $550,375	59,500 New	59,500 $416,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Davenport & CO LLC with notifications on news.